Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SLN

Silence Therapeutics Plc ADR

May 09 • 04:00PM ET

22.95

Dollar change +0.35
Percentage change 1.55	%

Healthcare • Biotechnology • United Kingdom • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.44	Insider Own	8.80%	Shs Outstand	39.62M	Perf Week	7.75%
Market Cap	909.28M	Forward P/E	-	EPS next Y	-0.49	Insider Trans	0.00%	Shs Float	36.13M	Perf Month	8.51%
Income	-53.74M	PEG	-	EPS next Q	-0.12	Inst Own	43.03%	Short Float	0.40%	Perf Quarter	8.25%
Sales	31.36M	P/S	28.99	EPS this Y	-1.95%	Inst Trans	-	Short Ratio	0.72	Perf Half Y	134.18%
Book/sh	0.55	P/B	41.83	EPS next Y	1.65%	ROA	-43.18%	Short Interest	0.15M	Perf Year	250.92%
Cash/sh	1.74	P/C	13.20	EPS next 5Y	-	ROE	-222.59%	52W Range	4.84 - 27.72	Perf YTD	32.12%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-6.72%	ROI	-245.90%	52W High	-17.21%	Beta	1.37
Dividend TTM	-	Quick Ratio	4.56	Sales past 5Y	474.55%	Gross Margin	58.73%	52W Low	374.17%	ATR (14)	1.07
Dividend Ex-Date	-	Current Ratio	4.56	EPS Y/Y TTM	7.22%	Oper. Margin	-196.65%	RSI (14)	59.05	Volatility	4.87% 4.77%
Employees	109	Debt/Eq	0.02	Sales Y/Y TTM	43.89%	Profit Margin	-171.35%	Recom	1.00	Target Price	57.75
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	-0.47%	Payout	-	Rel Volume	0.94	Prev Close	22.60
Sales Surprise	-69.67%	EPS Surprise	-94.84%	Sales Q/Q	-53.41%	Earnings	Mar 13 BMO	Avg Volume	202.39K	Price	22.95
SMA20	4.72%	SMA50	0.86%	SMA200	51.92%	Trades		Volume	189,822	Change	1.55%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-31-24	Initiated	BMO Capital Markets	Outperform	$67

Apr-30-24 08:30AM	Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference (Business Wire)
Apr-29-24 08:30AM	Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors (Business Wire)
Apr-12-24 08:21AM	Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains? (Zacks)
Apr-08-24 11:48AM	Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a) (Business Wire)
Mar-13-24 07:05AM	Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights (Business Wire)
07:00AM	Loading…
07:00AM	Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a) (Business Wire)
Feb-28-24 08:29AM	Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock? (Zacks)
08:00AM	Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024 (Business Wire)
Feb-23-24 08:00AM	Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial (Business Wire)
Feb-05-24 08:00AM	Silence Therapeutics Announces Oversubscribed $120 Million Private Placement (Business Wire)
Feb-01-24 08:19AM	Strength Seen in Silence Therapeutics PLC Sponsored ADR (SLN): Can Its 15.4% Jump Turn into More Strength? (Zacks)
Jan-31-24 07:00AM	Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (Business Wire) +15.44%
Jan-17-24 08:00AM	INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors (GlobeNewswire)
Jan-11-24 12:00PM	All You Need to Know About Silence Therapeutics PLC Sponsored ADR (SLN) Rating Upgrade to Strong Buy (Zacks)
Dec-01-23 07:00AM	Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments (Business Wire) +5.28%
07:00AM	Loading…
Nov-14-23 07:00AM	Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-08-23 07:00AM	Silence Therapeutics to Present at Jefferies London Healthcare Conference (Business Wire)
Nov-01-23 07:00AM	Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease (Business Wire) +29.25%
Sep-26-23 07:00AM	Silence Therapeutics to Participate in Fireside Chat at Chardans 7th Annual Genetic Medicines Conference (Business Wire)
Sep-06-23 07:00AM	Silence Therapeutics to Participate in September Investor Conferences (Business Wire) -5.70%
Aug-16-23 07:00AM	Silence Therapeutics Reports Second Quarter 2023 Results (Business Wire) +6.21%
Jul-11-23 07:00AM	Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration (Business Wire)
May-31-23 07:00AM	Silence Therapeutics to Present at the Jefferies Healthcare Conference (Business Wire) -8.61%
May-16-23 04:00PM	Silence Therapeutics Reports First Quarter 2023 Results (Business Wire)
May-04-23 07:00AM	Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration (Business Wire)
May-01-23 07:00AM	Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events (Business Wire)
Apr-25-23 07:00AM	Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor Conference (Business Wire)
Apr-04-23 07:00AM	Silence Therapeutics Announces Publication in Blood Demonstrating Role for Iron Regulation in Polycythemia Vera (Business Wire)
Mar-29-23 07:00AM	Silence Therapeutics to Present at Guggenheims Genomic Medicines and Rare Disease Days (Business Wire) -22.94%
Mar-28-23 07:05AM	Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development (Business Wire)

Silence Therapeutics Plc engages in the discovery, delivery, and development of ribonucleic acid (RNA) therapeutics. It also develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. The company was founded on November 18, 1994 and is headquartered in London, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SLN

Silence Therapeutics Plc ADR

Upgrade your FINVIZ experience